Potencjał zimnej plazmy atmosferycznej w przełamywaniu lekooporności nowotworów

Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299-309. doi:10.1038/s41586-019-1730-11.

Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nat Rev Cancer. 2022;22(6):323-339. doi:10.1038/s41568-022-00454-5

Chitcholtan K, Asselin E, Parent S, Sykes PH, Evans JJ. Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. Experimental Cell Research. 2013;319(1):75-87. doi:10.1016/j.yexcr.2012.09.012

Duan C, Yu M, Xu J, Li BY, Zhao Y, Kankala RK. Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomedicine & Pharmacotherapy. 2023;162:114643. doi:10.1016/j.biopha.2023.114643

Emami Nejad A, Najafgholian S, Rostami A, i in. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1). doi:10.1186/s12935-020-01719-5

Kato et al. Cancer Cell International 2013, 13:89 http://www.cancerci.com/content/13/1/89

Liu J, Yuan Y, Cheng Y, i in. Copper-Based Metal–Organic Framework Overcomes Cancer Chemoresistance through Systemically Disrupting Dynamically Balanced Cellular Redox Homeostasis. J Am Chem Soc. 2022;144(11):4799-4809. doi:10.1021/jacs.1c11856

Caccuri F, Sommariva M, Marsico S, i in. Inhibition of DNA Repair Mechanisms and Induction of Apoptosis in Triple Negative Breast Cancer Cells Expressing the Human Herpesvirus 6 U94. Cancers. 2019;11(7):1006. doi:10.3390/cancers11071006

Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance. Cancers. 2021;13(17):4363. doi:10.3390/cancers13174363

Bernhardt T, Semmler ML, Schäfer M, Bekeschus S, Emmert S, Boeckmann L. Plasma Medicine: Applications of Cold Atmospheric Pressure Plasma in Dermatology. Oxidative Medicine and Cellular Longevity. 2019;2019:1-10. doi:10.1155/2019/3873928

Shahzad A, Hanif F, Manzoor A, Ain Asif QU. Introductory Chapter: Progress of Plasma Physics and Allied Technologies in Daily Life Applications. Advancements in Fine Particle Plasmas. Published online 13 marzec 2024. doi:10.5772/intechopen.1002628

Khlyustova A, Labay C, Machala Z, Ginebra MP, Canal C. Important parameters in plasma jets for the production of RONS in liquids for plasma medicine: A brief review. Front Chem Sci Eng. 2019;13(2):238-252. doi:10.1007/s11705-019-1801-8

Tan F, Rui X, Xiang X, Yu Z, Al‐Rubeai M. Multimodal treatment combining cold atmospheric plasma and acidic fibroblast growth factor for multi‐tissue regeneration. FASEB j. 2021;35(5). doi:10.1096/fj.202002611r

Amini MR, Sheikh Hosseini M, Fatollah S, i in. Beneficial effects of cold atmospheric plasma on inflammatory phase of diabetic foot ulcers; a randomized clinical trial. J Diabetes Metab Disord. 2020;19(2):895-905. doi:10.1007/s40200-020-00577-2

Borchardt T, Ernst J, Helmke A, i in. Effect of direct cold atmospheric plasma (diCAP) on microcirculation of intact skin in a controlled mechanical environment. Microcirculation. 2017;24(8). doi:10.1111/micc.12399

Eisenhauer P, Chernets N, Song Y, i in. Chemical modification of extracellular matrix by cold atmospheric plasma-generated reactive species affects chondrogenesis and bone formation. J Tissue Eng Regen Med. 2016;10(9):772-782. doi:10.1002/term.2224

Dubuc A, Monsarrat P, Virard F, i in. Use of cold-atmospheric plasma in oncology: a concise systematic review. Ther Adv Med Oncol. 2018;10. doi:10.1177/1758835918786475

Zhang X, Wang M, Feng J, i in. Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer. J Nanobiotechnol. 2022;20(1). doi:10.1186/s12951-022-01377-x

Mateu-Sanz M, Tornín J, Ginebra MP, Canal C. Cold Atmospheric Plasma: A New Strategy Based Primarily on Oxidative Stress for Osteosarcoma Therapy. JCM. 2021;10(4):893. doi:10.3390/jcm10040893

Bauer G. The synergistic effect between hydrogen peroxide and nitrite, two long-lived molecular species from cold atmospheric plasma, triggers tumor cells to induce their own cell death. Redox Biology. 2019;26:101291. doi:10.1016/j.redox.2019.101291

Lukes P, Dolezalova E, Sisrova I, Clupek M. Aqueous-phase chemistry and bactericidal effects from an air discharge plasma in contact with water: evidence for the formation of peroxynitrite through a pseudo-second-order post-discharge reaction of H2O2and HNO2. Plasma Sources Sci Technol. 2014;23(1):015019. doi:10.1088/0963-0252/23/1/015019

de Sá Junior PL, Câmara DAD, Porcacchia AS, i in. The Roles of ROS in Cancer Heterogeneity and Therapy. Maraldi T, red. Oxidative Medicine and Cellular Longevity. 2017;2017(1). doi:10.1155/2017/2467940

Khlyustova A, Labay C, Machala Z, Ginebra MP, Canal C. Important parameters in plasma jets for the production of RONS in liquids for plasma medicine: A brief review. Front Chem Sci Eng. 2019;13(2):238-252. doi:10.1007/s11705-019-1801-8

Kurake N, Tanaka H, Ishikawa K, i in. Cell survival of glioblastoma grown in medium containing hydrogen peroxide and/or nitrite, or in plasma-activated medium. Archives of Biochemistry and Biophysics. 2016;605:102-108. doi:10.1016/j.abb.2016.01.011

Kumari S, Badana AK, G MM, G S, Malla R. Reactive Oxygen Species: A Key Constituent in Cancer Survival. Biomark�Insights. 2018;13. doi:10.1177/1177271918755391

Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes & Diseases. 2016;3(3):198-210. doi:10.1016/j.gendis.2016.04.007

Moody C, Wheelhouse R. The Medicinal Chemistry of Imidazotetrazine Prodrugs. Pharmaceuticals. 2014;7(7):797-838. doi:10.3390/ph7070797

Murillo D, Huergo C, Gallego B, Rodríguez R, Tornín J. Exploring the Use of Cold Atmospheric Plasma to Overcome Drug Resistance in Cancer. Biomedicines. 2023;11(1):208. doi:10.3390/biomedicines11010208

Hanif F, Muzaffar K, Perveen kahkashan, Malhi S, Simjee S. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. APJCP. 2017;18(1). doi:10.22034/APJCP.2017.18.1.3

Shaw P, Kumar N, Privat-Maldonado A, Smits E, Bogaerts A. Cold Atmospheric Plasma Increases Temozolomide Sensitivity of Three-Dimensional Glioblastoma Spheroids via Oxidative Stress-Mediated DNA Damage. Cancers. 2021;13(8):1780. doi:10.3390/cancers13081780

Köritzer J, Boxhammer V, Schäfer A, i in. Restoration of Sensitivity in Chemo — Resistant Glioma Cells by Cold Atmospheric Plasma. Lim M, red. PLoS ONE. 2013;8(5):e64498. doi:10.1371/journal.pone.0064498

Haar CP, Hebbar P, Wallace GC IV, i in. Drug Resistance in Glioblastoma: A Mini Review. Neurochem Res. 2012;37(6):1192-1200. doi:10.1007/s11064-011-0701-1

Gjika E, Pal-Ghosh S, Kirschner ME, i in. Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells. Sci Rep. 2020;10(1). doi:10.1038/s41598-020-73457-7

Soni V, Adhikari M, Simonyan H, i in. In Vitro and In Vivo Enhancement of Temozolomide Effect in Human Glioblastoma by Non-Invasive Application of Cold Atmospheric Plasma. Cancers. 2021;13(17):4485. doi:10.3390/cancers13174485

Kopacz-Bednarska A, Król T. Cisplatin — properties and clinical application. Oncol Clin Pract. Published online 31 maj 2022. doi:10.5603/ocp.2022.0020

Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorganic Chemistry. 2019;88:102925. doi:10.1016/j.bioorg.2019.102925

Lugones Y, Loren P, Salazar LA. Cisplatin Resistance: Genetic and Epigenetic Factors Involved. Biomolecules. 2022;12(10):1365. doi:10.3390/biom12101365

Brunner TF, Probst FA, Troeltzsch M, i in. Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro study. Head Face Med. 2022;18(1). doi:10.1186/s13005-022-00322-5

Li Y, Tang T, Lee HJ, Song K. Selective Anti-Cancer Effects of Plasma-Activated Medium and Its High Efficacy with Cisplatin on Hepatocellular Carcinoma with Cancer Stem Cell Characteristics. IJMS. 2021;22(8):3956. doi:10.3390/ijms22083956

Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sciences. 2021;278:119527. doi:10.1016/j.lfs.2021.119527

Sagwal SK, Pasqual-Melo G, Bodnar Y, Gandhirajan RK, Bekeschus S. Combination of chemotherapy and physical plasma elicits melanoma cell death via upregulation of SLC22A16. Cell Death Dis. 2018;9(12). doi:10.1038/s41419-018-1221-6

Zahedian S, Hekmat A, i in. The Impacts of Prepared Plasma-Activated Medium (PAM) Combined with Doxorubicin on the Viability of MCF-7 Breast Cancer Cells: A New Cancer Treatment Strategy. rbmb.net. 2022;10(4):640-652. doi:10.52547/rbmb.10.4.640

Mateu-Sanz M, Ginebra MP, Tornín J, Canal C. Cold atmospheric plasma enhances doxorubicin selectivity in metastasic bone cancer. Free Radical Biology and Medicine. 2022;189:32-41. doi:10.1016/j.freeradbiomed.2022.07.007

Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019;24(1). doi:10.1186/s11658-019-0164-y

Sharifi-Rad J, Quispe C, Patra JK, i in. Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy. De Oliveira FL, red. Oxidative Medicine and Cellular Longevity. 2021;2021(1). doi:10.1155/2021/3687700

Weaver BA. How Taxol/paclitaxel kills cancer cells. Bement W, red. MBoC. 2014;25(18):2677-2681. doi:10.1091/mbc.e14-04-0916

Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett. 2019;24(1). doi:10.1186/s11658-019-0164-y

Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Cancer Treatment Reviews. 2012;38(7):890-903. doi:10.1016/j.ctrv.2012.02.011

Froidevaux-Klipfel L, Targa B, Cantaloube I, Ahmed-Zaïd H, Poüs C, Baillet A. Septin cooperation with tubulin polyglutamylation contributes to cancer cell adaptation to taxanes. Oncotarget. 2015;6(34):36063-36080. doi:10.18632/oncotarget.5373

Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Front Pharmacol. 2021;12. doi:10.3389/fphar.2021.628690

Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Seminars in Cancer Biology. 2019;59:147-160. doi:10.1016/j.semcancer.2019.05.012

Mihai CT, Mihaila I, Pasare MA, Pintilie RM, Ciorpac M, Topala I. Cold Atmospheric Plasma-Activated Media Improve Paclitaxel Efficacy on Breast Cancer Cells in a Combined Treatment Model. CIMB. 2022;44(5):1995-2014. doi:10.3390/cimb44050135

Park S, Kim H, Ji HW, i in. Cold Atmospheric Plasma Restores Paclitaxel Sensitivity to Paclitaxel-Resistant Breast Cancer Cells by Reversing Expression of Resistance-Related Genes. Cancers. 2019;11(12):2011. doi:10.3390/cancers11122011

Ganesan M, Kanimozhi G, Pradhapsingh B, i in. Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways. Biomedicine & Pharmacotherapy. 2021;139:111632. doi:10.1016/j.biopha.2021.111632

Sivadasan D, Ramakrishnan K, Mahendran J, Ranganathan H, Karuppaiah A, Rahman H. Solid Lipid Nanoparticles: Applications and Prospects in Cancer Treatment. IJMS. 2023;24(7):6199. doi:10.3390/ijms24076199

Ye F, Dewanjee S, Li Y, i in. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1). doi:10.1186/s12943-023-01805-y

Mendes I, Vale N. How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy? IJMS. 2023;24(14):11855. doi:10.3390/ijms241411855

Jones O, Cheng X, Murthy SRK, i in. The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro. Sci Rep. 2021;11(1). doi:10.1038/s41598-021-88451-w

Lee S, Lee H, Jeong D, i in. Cold atmospheric plasma restores tamoxifen sensitivity in resistant MCF-7 breast cancer cell. Free Radical Biology and Medicine. 2017;110:280-290. doi:10.1016/j.freeradbiomed.2017.06.017